The functional consequences of protein polyubiquitination are determined by the type of ubiquitin chain assembled on the substrate. Among the eight known linkage types, lysine 48 (K48)-linked chains target proteins for proteasomal degradation, whereas lysine 63 (K63)-linked chains primarily regulate intracellular signaling, trafficking, autophagy, mitophagy, and mitochondrial biogenesis. Therapeutic strategies that exploit the ubiquitin–proteasome system […]
While direct K-RAS inhibitors represent a major therapeutic advance, targeting this oncoprotein remains a significant challenge due to limited druggable pockets, resistance mechanisms, and isoform diversity. Molecular glue–based targeted protein degradation (TPD) offers a promising alternative, overcoming key limitations of traditional inhibitors and PROTACs, including ADME/PK liabilities and reliance on a narrow set of E3 […]
Pan-selective Tandem Ubiquitin-Binding Entities (TUBEs) are engineered, high-affinity reagents composed of multiple ubiquitin-associated (UBA) domains that bind polyubiquitin chains with very high affinity. Their design enables pan-specific capture of all ubiquitin chain linkage types (K6, K11, K27, K29, K33, K48, K63, and M1)—overcoming the inherent bias of antibody-based methods like DiGly enrichment. Critically, TUBEs preserve […]
LifeSensors is pleased to bring attention to some of our academic colleagues who have used our products in the past to make discoveries and publications in the Ubiquitin Proteasome System field and further beyond. From E1s to SUMO expression, phosphorylation to deubiquitinases, we’re happy to have been a part of scientific discovery, and look forward […]
Different lysines on ubiquitin are involved in forming different ubiquitin chains, with K48-linked chains primarily signaling for proteasomal degradation, while other linkages, such as K63-linked chains, and single ubiquitin molecules (monoubiquitination) act as non-degradative signals for processes like DNA repair, signal transduction, and trafficking. Due to the diverse signaling and the multiple different lysines (K6, […]
The PA950 and PA770 are important assays for studying ubiquitination due to an E3 ligase or PROTAC, and the launch of the MG780 kit also extends this functionality to Molecular glues, opening up new options to test and verify functionality of compounds prior to later stage development, allowing ubiquitination to be confirmed which minimizes turnaround […]
By: Derrick Padykula and Isabelle Wentzel Hallmark of Neurodegeneration Diving into the complex world of neurodegeneration unveils the long road marked by the gradual decline of neuronal cells, ultimately leading to cell death. In Parkinson’s disease (PD) and Alzheimer’s disease (AD), the accumulation of aggregated proteins and dysfunctional mitochondria is what contributes to the demise of […]
By: Derrick Padykula Ubiquitination, a ubiquitous cellular process, involves attaching ubiquitin to target proteins, influencing crucial cellular functions such as degradation, cell signaling, apoptosis, protein processing, immune response, and DNA repair. The specific ubiquitin chain type, whether M1, K6, K11, K27, K29, K33, K48, or K63-linked, dictates the downstream processing of the target protein. Delving […]
MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, […]
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design Authors: Janelle Pedroza1, Kenneth Wallace1, Derrick Padykula, Alexandra Russell1, and Karteek Kadimisetty*1 Introduction PROTACs have emerged as new class of drugs that can target the “undruggable” proteome by hijacking the ubiquitin proteasome system. Traditional methods like western blotting and reporter gene assays are prone to […]
By: Abdul Haseeb, Ph.D. Drugging the Undruggable Tremendous progress in genomics, transcriptomics and proteomics has led to the discovery of thousands of new drivers of disease, but drug discovery is still catching up to these new potential drug targets because most of these new players are intractable to traditional pharmacological targeting. Traditional small molecule […]
MALVERN, Pa., SEP 1, 2022 – LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glues, and neurodegeneration diagnostics, is pleased to announce that Lifesensors has published a seminal paper: Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. This paper is published in the Biochemical and Biophysical […]
Dear Colleagues, Deciphering the Ubiquitin Code is the first step in utilizing the Ubiquitin Proteasome System (UPS) to drug the so-called undruggable targets. LifeSensors is proud to present a new technology which will allow for much more precise and accurate targeting of the UPS. The new K48 TUBE HF was developed to show enhanced selectivity […]
